Guardant Health Gains $100M
Redwood City-based Guardant Health, which is developing cell-free, DNA liquid biopsy technology for cancer testing via blood samples, said today that it has raised $100M in a Series D funding. The funding was led by OrbiMed Advisors, and also included Khosla Ventures, Sequoia Capital, Lightspeed Venture Partners, Pejman Mar, Formation 8, and Heritage Group. The company says it has now raised nearly $200M in total. Guardant Health is led by Helmy Eltoukhy.
posted on Thursday, January 7, 2016 (Link to more information)
Related companies:
Guardant Health, Inc.
Related stories:
> Guardant Health Gets $360M
> Guardant Health Snags $30M For Tumor Sequencing
> Guardant Health Finds $50M
> Clover Health Finds $100M For Tech Enabled Health Insurance
> Castlight Health Finds $100M More
silicontap.com Home